Pulmonary hypertension (PH) is a devastating disease that leads to right heart failure and death. Despite recent advances in drug therapy and improvements in patient care, PH remains a fatal disease. Thus, a mechanism-based breakthrough is imperative to identify novel targets and discover innovative strategies to control and potentially cure PH. Our findings suggest that a dysfunctional gut-angiotensin converting enzyme 2 (ACE2)-lung interaction represents this breakthrough. ACE2 is a key gut epithelial cell enzyme of the renin-angiotensin system (RAS), produces angiotensin-(1-7) and together constitutes the vasoprotective axis of the RAS and opposes the fibrotic, proliferative, and inflammatory effects of angiotensin II. We propose that risk factors for PH exert profound influences on the gut resulting in a decrease in gut ACE2. This initiates a series of events key in the establishment of PH. They include increases in gut permeability, inflammation, and microbial dysbiosis. Collectively, they contribute to inflammation, endothelial dysfunction and microvascular pathophysiology. Therefore, we hypothesize that PH is caused by gut ACE2 deficiency-mediated increases in High-Mobility Group Protein B1 (HMGB1) signaling and microbial dysbiosis. Hence, increases in gut ACE2 would decrease HMGB1, reestablish eubiosis and attenuate/reverse PH pathophysiology. This innovative hypothesis is supported by our data and evidence from the literature. However, many questions remain: Are changes in gut permeability and dysbiosis prevalent in PH patients? What is the mechanism of ACE2-mediated gut dysbiosis? How do gut dysbiosis-induced changes impact PH? We propose following aims to address these issues: 1) Investigate the hypothesis that a decrease in intestinal ACE2 results in increased gut permeability, inflammation and dysbiosis, which leads to the development of PH; 2) Investigate the hypothesis that ACE2-induced changes in the gut are mediated by HMGB1; 3) Evaluate the hypothesis that oral ACE2 feeding improves gut barrier properties and rebalances microbial community to protect against PH; 4) Test the impact of gut dysbiosis in PH patients. Results of this study will support our concept that ACE2-mediated dysfunctional gut-lung communication is critical in PH and provide clinical validity for our hypothesis. Thus, the outcome will be valuable for the development of ?paradigm-changing? approaches involving oral supplementation of ACE2 for PH.

Public Health Relevance

Pulmonary hypertension (PH) is a devastating disease that leads to right heart failure and death. Despite recent advances in drug therapy, PH remains a fatal disease. We propose that a dysfunctional gut-lung communication mediated by angiotensin converting enzyme2 (ACE2) is critical in the development and establishment of PH pathophysiology. A decreased expression of gut ACE2 increases permeability, and induces gut microbial dysbiosis and inflammation. This process produces mediators, cytokines and bacterial metabolites that adversely impact lung physiology and induce PH. Thus, we propose to test this hypothesis in both animal models and PH patients. We will also evaluate an innovative technology that would increase gut ACE2 and correct dysbiosis in PH. We believe that the outcome of this study will be valuable immediately for development of novel approaches involving oral supplementation of ACE2 for PH treatment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL102033-09
Application #
9724509
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Xiao, Lei
Project Start
2010-05-01
Project End
2020-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Florida
Department
Physiology
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Rathinasabapathy, Anandharajan; Horowitz, Alana; Horton, Kelsey et al. (2018) The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Front Physiol 9:180
Cole-Jeffrey, Colleen T; Pepine, Carl J; Katovich, Michael J et al. (2018) Beneficial Effects of Angiotensin-(1-7) on CD34+ Cells From Patients With Heart Failure. J Cardiovasc Pharmacol 71:155-159
Oliveira, Aline C; Sharma, Ravindra K; Aquino, Victor et al. (2018) Involvement of Microglial Cells in Hypoxia-induced Pulmonary Hypertension. Am J Respir Cell Mol Biol 59:271-273
Sharma, Ravindra K; Oliveira, Aline C; Kim, Seungbum et al. (2018) Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension. Hypertension 71:1156-1163
Richards, Elaine M; Raizada, Mohan K (2018) ACE2 and pACE2: A Pair of Aces for Pulmonary Arterial Hypertension Treatment? Am J Respir Crit Care Med 198:422-423
Richards, Elaine M; Pepine, Carl J; Raizada, Mohan K et al. (2017) The Gut, Its Microbiome, and Hypertension. Curr Hypertens Rep 19:36
Qi, YanFei; Goel, Ruby; Kim, Seungbum et al. (2017) Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging. J Am Med Dir Assoc 18:810.e1-810.e4
Raizada, Mohan K; Joe, Bina; Bryan, Nathan S et al. (2017) Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation: Current Status and Future Directions. Hypertension :
Qi, YanFei; Kim, Seungbum; Richards, Elaine M et al. (2017) Gut Microbiota: Potential for a Unifying Hypothesis for Prevention and Treatment of Hypertension. Circ Res 120:1724-1726
Rathinasabapathy, Anandharajan; Bruce, Erin; Espejo, Andrew et al. (2016) Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br J Pharmacol 173:2859-79

Showing the most recent 10 out of 38 publications